Elisabeth A. Bone

Medicine · Health Sciences

22h-index2.3kcitations57works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Peptidase Inhibition and Analysis(28), Histone Deacetylase Inhibitors Research(18), Protease and Inhibitor Mechanisms(9), Protein Degradation and Inhibitors(9), Signaling Pathways in Disease(6)

Publications57 total

Figures S1 - S6 from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2023Open Access
Supplementary Tables S1-S8 from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2023Open Access
Data from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2023Open Access
Figures S1 - S6 from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2023Open Access
Data from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2023Open Access
Supplementary Tables S1-S8 from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2023Open Access
Supplementary Table 4 from CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells
2023Open Access
Supplementary Methods and Materials from CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells
2023Open Access
Supplementary Methods and Materials from CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells
2023Open Access
Supplementary Table 4 from CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells
2023Open Access
Data from CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells
2023Open Access
Data from CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells
2023Open Access
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma
Leukemia & lymphoma/Leukemia and lymphoma·2021· 7 cited
Pharmacokinetics of KA2237, a novel selective inhibitor of PI3K-β and PI3K-δ, in patients: A first-in-human study using PK modelling to predict drug concentrations during dose escalation
2021Open Access
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
Clinical Cancer Research·2021· 61 citedOpen Access
92P Characterising the role of HDAC6 in the control of human macrophage IL-10 production
Annals of Oncology·2020Open Access
Drug Targeting to Monocytes and Macrophages Using Esterase-Sensitive Chemical Motifs
Journal of Pharmacology and Experimental Therapeutics·2011· 68 cited
Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-<i>N</i>-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor
Journal of Medicinal Chemistry·2010· 82 citedOpen Access
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours
British Journal of Cancer·2010· 30 citedOpen Access
Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia
Journal of Clinical Oncology·2010· 74 cited
page 1 of 3Next →

Frequent Co-authors

Alan H. Drummond(8), Lindsay J. Bawden(7), Philip Beer(7), Kemal Haque(7), Hilary McElwaine-Johnn(7), R.G.G. Russell(7), Annette Wright(6), Lindsey Needham(6), Vanessa Clark(6), Alexander Cecil(6), Franck A. Silva(6), Stephen Chandler(5), Alan H. Davidson(5), L. Michael Wood(5), Robert H. Michell(5), David Krige(5), Nicolás Flores(5), Valérie Legris(5), Gary Box(5), David Laber(5)